Novel Small-Molecule Inhibitors of the Vascular Endothelial Growth Factor Receptor

Senger, 1983, Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid, Science, 219, 983, 10.1126/science.6823562 Ferrara, 1989, Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells, Biochem Biophys Res Commun, 161, 851, 10.1016/0006-291X(89)92678-8 Connolly, 1989, Human vascular permeability factor. Isolation from U937 cells, J Biol Chem, 264, 20017, 10.1016/S0021-9258(19)47212-8 Ferrara, 1991, The vascular endothelial growth factor family of polypeptides, J Cell Biochem, 47, 211, 10.1002/jcb.240470305 Folkman, 1995, Angiogenesis inhibitors generated by tumors, Mol Med, 1, 120, 10.1007/BF03401559 Montironi, 1996, Analysis of the capillary architecture in the precursors of prostate cancer: recent findings and new concepts, Eur Urol, 30, 191, 10.1159/000474169 Singh, 1996, Regulation of tumor angiogenesis by organ-specific cytokines, Curr Top Microbiol Immunol, 213, 1, 10.1007/978-3-642-61109-4_1 Ellis, 1996, Angiogenesis and metastasis, Eur J Cancer, 32A, 2451, 10.1016/S0959-8049(96)00389-9 Breslin, 2003, VEGF increases endothelial permeability by separate signaling pathways involving ERK-1/2 and nitric oxide, Am J Physiol Heart Circ Physiol, 284, H92, 10.1152/ajpheart.00330.2002 Shibuya, 1990, Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family, Oncogene, 5, 519 Terman, 1992, Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor, Biochem Biophys Res Commun, 187, 1579, 10.1016/0006-291X(92)90483-2 Brown, 1993, Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract, Cancer Res, 53, 4727 Paz, 2005, Development of angiogenesis inhibitors to vascular endothelial growth factor receptor 2. Current status and future perspective, Frontier Biosci, 10, 1415, 10.2741/1629 Dvorak, 2002, Vascular permeability factor/vascular endothelial growth factor: critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy, J Clin Oncol, 20, 4368, 10.1200/JCO.2002.10.088 Hicklin, 2005, Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis, J Clin Oncol, 23, 1011, 10.1200/JCO.2005.06.081 Karpanen, 2001, Lymphatic vessels as targets of tumor therapy?, J Exp Med, 194, F37, 10.1084/jem.194.6.F37 Valtola, 1999, VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer, Am J Pathol, 154, 1381, 10.1016/S0002-9440(10)65392-8 Partanen, 1999, Lack of lymphatic vascular specificity of vascular endothelial growth factor receptor 3 in 185 vascular tumors, Cancer, 86, 2406, 10.1002/(SICI)1097-0142(19991201)86:11<2406::AID-CNCR31>3.0.CO;2-E Ferrara, 2003, The biology of VEGF and its receptors, Nat Med, 9, 669, 10.1038/nm0603-669 Dy, 2006, Angiogenesis inhibitors in lung cancer: a promise fulfilled, Clin Lung Cancer, 7, S145, 10.3816/CLC.2006.s.006 Herbst, 2005, Angiogenesis and lung cancer: prognostic and therapeutic implications, J Clin Oncol, 23, 3243, 10.1200/JCO.2005.18.853 Inai, 2004, Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts, Am J Pathol, 165, 35, 10.1016/S0002-9440(10)63273-7 Rugo, 2005, Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results, J Clin Oncol, 23, 5474, 10.1200/JCO.2005.04.192 Rini, 2005, AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a phase 2 study of cytokine-refractory, metastatic renal cell cancer (RCC), J Clin Oncol, 23, 380s, 10.1200/jco.2005.23.16_suppl.4509 Wedge, 2005, AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer, Cancer Res, 65, 4389, 10.1158/0008-5472.CAN-04-4409 Drevs, 2005, Phase I clinical evaluation of AZD2171, a highly potent VEGF receptor tyrosine kinase inhibitor, in patients with advanced tumors, J Clin Oncol, 23, 192s Lorusso, 2006, Phase I evaluation of AZD2171, a highly potent and selective inhibitor of VEGFR signaling, in combination with selected chemotherapy regimens in patients with advanced solid tumors, J Clin Oncol, 24, 129s Podar, 2006, In vitro and in vivo activity of the VEGF receptor inhibitor pazopanib (GW786034) in Multiple Myeloma: therapeutic implications, Proc Am Assoc Cancer Res, 47 Hurwitz, 2005, Tolerability and pharmacokinetics of oral administration of GW786034 in pts with solid tumors, J Clin Oncol, 23, 195s Suttle, 2004, Pharmacokinetics (PK) and tolerability of GW786034, a VEGFR tyrosine kinase inhibitor, after daily oral administration to patients with solid tumors, J Clin Oncol, 22, 208 Sikic, 2006, A phase I dose-escalation and pharmacokinetic study of XL647, a novel spectrum selective kinase inhibitor administered orally to patients with advanced solid malignancies, Eur J Cancer, 4, 35 Halaban, 1993, White mutants in mice shedding light on humans, J Invest Dermatol, 100, 176S, 10.1038/jid.1993.73 Tsatsaris, 2003, Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathophysiological consequences, J Clin Endocrinol Metab, 88, 5555, 10.1210/jc.2003-030528 McKeeman, 2004, Soluble vascular endothelial growth factor receptor-1 (sFlt-1) is increased throughout gestation in patients who have preeclampsia develop, Am J Obstet Gynecol, 191, 1240, 10.1016/j.ajog.2004.03.004 Glusker, 2006, Reversible posterior leukoencephalopathy syndrome and bevacizumab, N Engl J Med, 354, 980, 10.1056/NEJMc052954 Cines, 1998, Endothelial cells in physiology and in the pathophysiology of vascular disorders, Blood, 91, 3527 Pinedo, 2003, The role of VEGF in oncology: effects on hemostatic and thrombosis, Pathophysiol Haemost Thromb, 33, 11, 10.1159/000073280 Hurwitz, 2004, Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer, N Engl J Med, 350, 2335, 10.1056/NEJMoa032691